Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-hodgkin's lymphoma

Julie Marie Vose, David Colcher, Lisa Gobar, Philip Jay Bierman, Samuel Augustine, Margaret Tempero, Peter Leichner, James C. Lynch, David Goldenberg, James Olen Armitage

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The purpose of this to evaluate in a phase I/II study the efficacy and toxicity of a multi-dose administration of 131I labeled CD22 monoclonal antibody (131I-MAb-LL2) in escalating dose cohorts administered to relapsed non-Hodgkin's lymphoma (NHL) patients. Twenty-one patients with relapsed NHL received one of four dose levels of 131I-MAb-LL2 administered in a twice weekly pattern. Starting with dose level 2, the patients also received 20 mg of unlabeled LL2 prior to each radiolabeled dose administered. Previously stored autologous peripheral blood progenitors were reinfused in case of prolonged cytopenias. Patients could repeat the same treatment if they had stable disease or a response to the first therapy at 8 weeks, and had not received their peripheral blood progenitors with the first cycle. Combining all of the dose cohorts, there were 5 complete responses or complete responses (undetermined) and 2 partial responses for a total response rate of 7/21 (33%). There was no dose response effect with responses documented at all dose levels. Expected toxicities were hematopoietic, requiring stem cell re-infusion in 5 patients. Other toxicities included hypothyroidism in 3 patients, and human anti-mouse antibody formation (HAMA) in 4 patients. In conclusion, 131I-MAb-LL2, when administered in a multi-dose fashion with 20 mg unlabeled antibody pre-dosing, resulted in a response rate of 33% in heavily pre-treated NHL patients. Non-hematologic toxicities were mild and few in number. Further evaluation of this treatment is warranted and further dose escalation will be possible.

Original languageEnglish (US)
Pages (from-to)91-101
Number of pages11
JournalLeukemia and Lymphoma
Volume38
Issue number1-2
StatePublished - May 9 2000

Fingerprint

Non-Hodgkin's Lymphoma
Hematopoietic Stem Cells
Hypothyroidism
Antibody Formation
Anti-Idiotypic Antibodies
Therapeutics
Monoclonal Antibodies
Antibodies

Keywords

  • Anti-CD22
  • Iodine labelled
  • Monoclonal antibody
  • Recurrent non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-hodgkin's lymphoma. / Vose, Julie Marie; Colcher, David; Gobar, Lisa; Bierman, Philip Jay; Augustine, Samuel; Tempero, Margaret; Leichner, Peter; Lynch, James C.; Goldenberg, David; Armitage, James Olen.

In: Leukemia and Lymphoma, Vol. 38, No. 1-2, 09.05.2000, p. 91-101.

Research output: Contribution to journalArticle

Vose, JM, Colcher, D, Gobar, L, Bierman, PJ, Augustine, S, Tempero, M, Leichner, P, Lynch, JC, Goldenberg, D & Armitage, JO 2000, 'Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-hodgkin's lymphoma', Leukemia and Lymphoma, vol. 38, no. 1-2, pp. 91-101.
Vose, Julie Marie ; Colcher, David ; Gobar, Lisa ; Bierman, Philip Jay ; Augustine, Samuel ; Tempero, Margaret ; Leichner, Peter ; Lynch, James C. ; Goldenberg, David ; Armitage, James Olen. / Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-hodgkin's lymphoma. In: Leukemia and Lymphoma. 2000 ; Vol. 38, No. 1-2. pp. 91-101.
@article{cee8cf8a770c486d96cc854e7e6010bd,
title = "Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-hodgkin's lymphoma",
abstract = "The purpose of this to evaluate in a phase I/II study the efficacy and toxicity of a multi-dose administration of 131I labeled CD22 monoclonal antibody (131I-MAb-LL2) in escalating dose cohorts administered to relapsed non-Hodgkin's lymphoma (NHL) patients. Twenty-one patients with relapsed NHL received one of four dose levels of 131I-MAb-LL2 administered in a twice weekly pattern. Starting with dose level 2, the patients also received 20 mg of unlabeled LL2 prior to each radiolabeled dose administered. Previously stored autologous peripheral blood progenitors were reinfused in case of prolonged cytopenias. Patients could repeat the same treatment if they had stable disease or a response to the first therapy at 8 weeks, and had not received their peripheral blood progenitors with the first cycle. Combining all of the dose cohorts, there were 5 complete responses or complete responses (undetermined) and 2 partial responses for a total response rate of 7/21 (33{\%}). There was no dose response effect with responses documented at all dose levels. Expected toxicities were hematopoietic, requiring stem cell re-infusion in 5 patients. Other toxicities included hypothyroidism in 3 patients, and human anti-mouse antibody formation (HAMA) in 4 patients. In conclusion, 131I-MAb-LL2, when administered in a multi-dose fashion with 20 mg unlabeled antibody pre-dosing, resulted in a response rate of 33{\%} in heavily pre-treated NHL patients. Non-hematologic toxicities were mild and few in number. Further evaluation of this treatment is warranted and further dose escalation will be possible.",
keywords = "Anti-CD22, Iodine labelled, Monoclonal antibody, Recurrent non-Hodgkin's lymphoma",
author = "Vose, {Julie Marie} and David Colcher and Lisa Gobar and Bierman, {Philip Jay} and Samuel Augustine and Margaret Tempero and Peter Leichner and Lynch, {James C.} and David Goldenberg and Armitage, {James Olen}",
year = "2000",
month = "5",
day = "9",
language = "English (US)",
volume = "38",
pages = "91--101",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-hodgkin's lymphoma

AU - Vose, Julie Marie

AU - Colcher, David

AU - Gobar, Lisa

AU - Bierman, Philip Jay

AU - Augustine, Samuel

AU - Tempero, Margaret

AU - Leichner, Peter

AU - Lynch, James C.

AU - Goldenberg, David

AU - Armitage, James Olen

PY - 2000/5/9

Y1 - 2000/5/9

N2 - The purpose of this to evaluate in a phase I/II study the efficacy and toxicity of a multi-dose administration of 131I labeled CD22 monoclonal antibody (131I-MAb-LL2) in escalating dose cohorts administered to relapsed non-Hodgkin's lymphoma (NHL) patients. Twenty-one patients with relapsed NHL received one of four dose levels of 131I-MAb-LL2 administered in a twice weekly pattern. Starting with dose level 2, the patients also received 20 mg of unlabeled LL2 prior to each radiolabeled dose administered. Previously stored autologous peripheral blood progenitors were reinfused in case of prolonged cytopenias. Patients could repeat the same treatment if they had stable disease or a response to the first therapy at 8 weeks, and had not received their peripheral blood progenitors with the first cycle. Combining all of the dose cohorts, there were 5 complete responses or complete responses (undetermined) and 2 partial responses for a total response rate of 7/21 (33%). There was no dose response effect with responses documented at all dose levels. Expected toxicities were hematopoietic, requiring stem cell re-infusion in 5 patients. Other toxicities included hypothyroidism in 3 patients, and human anti-mouse antibody formation (HAMA) in 4 patients. In conclusion, 131I-MAb-LL2, when administered in a multi-dose fashion with 20 mg unlabeled antibody pre-dosing, resulted in a response rate of 33% in heavily pre-treated NHL patients. Non-hematologic toxicities were mild and few in number. Further evaluation of this treatment is warranted and further dose escalation will be possible.

AB - The purpose of this to evaluate in a phase I/II study the efficacy and toxicity of a multi-dose administration of 131I labeled CD22 monoclonal antibody (131I-MAb-LL2) in escalating dose cohorts administered to relapsed non-Hodgkin's lymphoma (NHL) patients. Twenty-one patients with relapsed NHL received one of four dose levels of 131I-MAb-LL2 administered in a twice weekly pattern. Starting with dose level 2, the patients also received 20 mg of unlabeled LL2 prior to each radiolabeled dose administered. Previously stored autologous peripheral blood progenitors were reinfused in case of prolonged cytopenias. Patients could repeat the same treatment if they had stable disease or a response to the first therapy at 8 weeks, and had not received their peripheral blood progenitors with the first cycle. Combining all of the dose cohorts, there were 5 complete responses or complete responses (undetermined) and 2 partial responses for a total response rate of 7/21 (33%). There was no dose response effect with responses documented at all dose levels. Expected toxicities were hematopoietic, requiring stem cell re-infusion in 5 patients. Other toxicities included hypothyroidism in 3 patients, and human anti-mouse antibody formation (HAMA) in 4 patients. In conclusion, 131I-MAb-LL2, when administered in a multi-dose fashion with 20 mg unlabeled antibody pre-dosing, resulted in a response rate of 33% in heavily pre-treated NHL patients. Non-hematologic toxicities were mild and few in number. Further evaluation of this treatment is warranted and further dose escalation will be possible.

KW - Anti-CD22

KW - Iodine labelled

KW - Monoclonal antibody

KW - Recurrent non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=18244429971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244429971&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 91

EP - 101

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -